Center for Translational Research AB (CTR) expands by acquiring Zelmic AB, the GMP-approved Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), specialized in development of topical and transdermal pharmaceutical formulations and drug delivery. The acquisition further expands CTRs portfolio, within pharmaceutical, regulatory, and clinical development to the CTR group.

Karin Meyer, CEO at CTR says: ”The addition of Zelmic in our company group will enable us to offer a more integrated approach that will benefit our current and new customers. Zelmic share our vision regarding the importance of quality and high scientific knowledge combined with solid experiences in drug development. We already have a proven track record of excellent collaboration with the team at Zelmic, and I look forward to extending this further”.

”We are truly thrilled to join this dynamic group”, says David Sagna, CEO Zelmic AB. “By integrating our specialized expertise in topical drug development with the broader pharmaceutical, regulatory, and clinical capabilities of the CTR group, we can offer our clients even more comprehensive and innovative solutions. CTR’s responsive approach to clinical and pharmaceutical development aligns perfectly with Zelmic’s vision for continued growth, aiming to become the preferred Nordic partner for drug development. I am very optimistic about our future and see great synergistic potential in continuing our journey”.

Picture showing David Sagna, CEO Zelmic and Karin Meyer, CEO CTR

About Center for Translational Research 
Center for Translational Research AB (CTR) is a group of companies providing expert services and advice for product development in life sciences. CTR currently has nine subsidiaries supporting the pharmaceutical and medical technology industry: CTC Clinical Trial Consultants AB, Lablytica Life Science AB, RegSmart Life Science AB, Toxicology Knowledge Team Sweden AB, RegFile AB, Metasafe AB, QAlliance AB, CTC Netherlands and Zelmic AB. CTR is building a robust and sustainable translational research organization with the critical mass of experts and financial stability needed to support our national and international life science clients with improved treatments for patients.

About Zelmic
Zelmic AB is a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) established in 2002, specialized in topical pharmaceuticals. The expertise includes drug delivery and product development for small molecules, peptides, and proteins, with services such as pre-formulation, GMP analysis, validation, and ICH stability studies. The company also offers GMP manufacturing for non-sterile products and conducts in-vitro performance testing (GMP), including IVRT and IVPT on skin, nails, and mucous membranes.
Located In Lund, conveniently connected with greater Copenhagen and in the center of Medicon Valley, home to numerous life science companies.

Press contacts
Karin Meyer, CEO, Center for Translational Research AB (CTR AB)
+46 (0) 76 855 9648

David Sagna, CEO, Zelmic AB
+46 (0)46 161242
LinkedIn /ctr-sweden